Genmab | GEN - Equity Capital And Reserves


Genmab reported DKK5.96B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Almirall EUR 1.53B 43.26M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
argenx SE USD 8.42B 1.09B Jun/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
Bayer EUR 29.71B 863M Jun/2026
BioMarin Pharmaceutical USD 6.32B 109.58M Jun/2026
Demant DKK 11.24B 1.4B Jun/2026
Exelixis USD 1.84B 91.99M Jun/2026
Fresenius Medical Care EUR 13.53B 673.44M Jun/2026
Genmab DKK 5.96B 275M Jun/2026
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GN Store Nord DKK 10.27B 146M Jun/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Insmed USD 757.49M 52.64M Jun/2026
Lakefront Biotherapeutics EUR 3.26B 10.26M Jun/2026
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 30.17B 430M Jun/2026
Novartis USD 41.95B 3.02B Jun/2026
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
Sanofi EUR 69.57B 3.24B Jun/2026
UCB EUR 10.87B 1.18B Dec/2025